lifestyle.sourcefed.com

Author: SeaStar Medical

SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026

March 30, 2026
SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 25, 2026
SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026

March 18, 2026
SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI

March 5, 2026
SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)

February 12, 2026
SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference

January 29, 2026